Biocept
Biocept, Cleared4 Partner to Provide COVID-19 Testing, Management Service
The companies are developing a system using Cleared4's health validation platform to allow Biocept COVID-19 customers to monitor and manage their testing programs.
Biocept Q1 Revenues Up Dramatically as COVID-19 Testing Boost Lingers
The company accessioned 145,100 total samples in the quarter, 144,932 of which were billable samples, driven largely by provision of PCR SARS-CoV-2 detection assays.
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
Biocept Q4 Revenues Spike as COVID-19 Testing Continues to Soar, Core Cancer Tests Lag
The firm's fourth quarter revenues included $18.3 million in commercial test revenue, of which $17.6 million was attributable to COVID-19 tests.
May 13, 2020
Biocept Q1 Revenues Up 41 Percent
Apr 27, 2020
Biocept Files $100M Shelf Registration
Apr 14, 2020
Biocept Prices $10.3M Direct Offering of Shares
Mar 2, 2020